Acorah Software Products - Accounts Production 16.5.460 false true true 31 December 2023 1 January 2023 false 1 January 2024 31 December 2024 31 December 2024 13091383 Mr A Akhtyrskyi A. Akhtyrskyi true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13091383 2023-12-31 13091383 2024-12-31 13091383 2024-01-01 2024-12-31 13091383 frs-core:CurrentFinancialInstruments 2024-12-31 13091383 frs-core:BetweenOneFiveYears 2024-12-31 13091383 frs-core:WithinOneYear 2024-12-31 13091383 frs-core:ShareCapital 2024-12-31 13091383 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 13091383 frs-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13091383 frs-bus:FilletedAccounts 2024-01-01 2024-12-31 13091383 frs-bus:SmallEntities 2024-01-01 2024-12-31 13091383 frs-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 13091383 frs-bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13091383 frs-bus:OrdinaryShareClass1 2024-01-01 2024-12-31 13091383 frs-bus:OrdinaryShareClass1 2024-12-31 13091383 1 2024-01-01 2024-12-31 13091383 frs-core:UnlistedNon-exchangeTraded 2024-12-31 13091383 frs-core:UnlistedNon-exchangeTraded 2023-12-31 13091383 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2023-12-31 13091383 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 13091383 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-12-31 13091383 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2023-12-31 13091383 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-12-31 13091383 frs-bus:Director1 2024-01-01 2024-12-31 13091383 frs-countries:EnglandWales 2024-01-01 2024-12-31 13091383 2022-12-31 13091383 2023-12-31 13091383 2023-01-01 2023-12-31 13091383 frs-core:CurrentFinancialInstruments 2023-12-31 13091383 frs-core:BetweenOneFiveYears 2023-12-31 13091383 frs-core:WithinOneYear 2023-12-31 13091383 frs-core:ShareCapital 2023-12-31 13091383 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31 13091383 frs-bus:OrdinaryShareClass1 2023-01-01 2023-12-31
Registered number: 13091383
AAA Management Corporation Ltd
Unaudited Financial Statements
For The Year Ended 31 December 2024
Contents
Page
Statement of Financial Position 1
Notes to the Financial Statements 2—5
Page 1
Statement of Financial Position
Registered number: 13091383
2024 2023
Notes £ £ £ £
FIXED ASSETS
Investments 4 1,781,037 1,781,000
1,781,037 1,781,000
CURRENT ASSETS
Receivables 5 1,539 100
Cash at bank and in hand 63,475 285,773
65,014 285,873
Payables: Amounts Falling Due Within One Year 6 (262,218 ) (227,287 )
NET CURRENT ASSETS (LIABILITIES) (197,204 ) 58,586
TOTAL ASSETS LESS CURRENT LIABILITIES 1,583,833 1,839,586
NET ASSETS 1,583,833 1,839,586
CAPITAL AND RESERVES
Called up share capital 7 100 100
Income Statement 1,583,733 1,839,486
SHAREHOLDERS' FUNDS 1,583,833 1,839,586
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Income Statement.
On behalf of the board
Mr A Akhtyrskyi
Director
01/09/2025
The notes on pages 2 to 5 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
AAA Management Corporation Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13091383 . The registered office is 12 Mulberry Place, Pinnell Road, London, SE9 6AR.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The functional currency of the company is considered to be pound sterling (£) because that is the currency of the primary economic environment in which the company operates. The financial statements are presented in pound sterling (£).
2.2. Going Concern Disclosure
The director has considered the company's financial position, liquidity and future performance together with financial projections for the company over the foreseeable future. After making enquiries, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, he continues to adopt the going concern basis in preparing the annual financial statements.
2.3. Leasing and Hire Purchase Contracts
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to income statement on a straight line basis over the lease term.
2.4. Financial Instruments
The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.
2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.6. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
Page 2
Page 3
2.7. Investments
Unlisted investments are stated at historical cost less provision for any diminution in value.
2.8. Receivables
Receivables are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables.
2.9. Payables
Payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.
3. Average Number of Employees
Average number of employees during the year was: NIL (2023: NIL)
- -
4. Investments
Unlisted
£
Cost
As at 1 January 2024 1,781,000
Additions 37
As at 31 December 2024 1,781,037
Provision
As at 1 January 2024 -
As at 31 December 2024 -
Net Book Value
As at 31 December 2024 1,781,037
As at 1 January 2024 1,781,000
Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzkykh tsin Poltava", a company incorporated in Ukraine. The principal activity of  LLC "Apteka nyzkykh tsin Poltava" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyzkykh tsin Poltava" was £305,774 and the aggregate amount of capital and reserves at the end of the year was £364,365.
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzkykh tsin K", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyzkykh tsin K" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyzkykh tsin K" was £450,161 and the aggregate amount of capital and reserves at the end of the year was £362,905.
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzkykh tsin!", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyzkykh tsin!" is that of retail trade of pharmaceutical goods in specialised stores. The loss for the financial year ending 31/12/2024 of LLC "Apteka nyzkykh tsin!" was £563,140 and the aggregate amount of capital and reserves at the end of the year was -£554,882.
...CONTINUED
Page 3
Page 4
4. Investments - continued
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzkykh tsin Dnipro", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyzkykh tsin Dnipro" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyzkykh tsin Dnipro" was £314,763 and the aggregate amount of capital and reserves at the end of the year was £244,339.
The company holds 60% of ordinary voting rights and shares of LLC "Apteka Kopiika", a company incorporated in Ukraine. The principal activity of LLC "Apteka Kopiika" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka Kopiika" was £391,324  and the aggregate amount of capital and reserves at the end of the year was £293,450.
The company holds 60% of ordinary voting rights and shares of LLC "Blagodiya", a company incorporated in Ukraine. The principal activity of LLC "Blagodiya"  is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Blagodiya" was £453,542 and the aggregate amount of capital and reserves at the end of the year was £379,619.
The company holds 60% of ordinary voting rights and shares of PE "Ekspres-Apteka", a company incorporated in Ukraine. The principal activity of PE "Ekspres-Apteka" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of PE "Ekspres-Apteka" was £100,713 and the aggregate amount of capital and reserves at the end of the year was -£63,710.
The company holds 60% of ordinary voting rights and shares of LLC "Farmasha", a company incorporated in Ukraine. The principal activity of LLC "Farmasha" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Farmasha" was £231,871 and the aggregate amount of capital and reserves at the end of the year was £199,869.
The company holds 60% of ordinary voting rights and shares of LLC "Apteka nyzkykh tsin Lviv", a company incorporated in Ukraine. The principal activity of LLC "Apteka nyzkykh tsin Lviv" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Apteka nyzkykh tsin Lviv" was £244,846 and the aggregate amount of capital and reserves at the end of the year was £234,513.
The company holds 60% of ordinary voting rights and shares of LLC "Avis-Pharma", a company incorporated in Ukraine. The principal activity of LLC "Avis-Pharma" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Avis-Pharma" was £128,754 and the aggregate amount of capital and reserves at the end of the year was £468,053.
The company holds 60% of ordinary voting rights and shares of LLC "Orchid-Pharm", a company incorporated in Ukraine. The principal activity of LLC "Orchid-Pharm" is that of retail trade of pharmaceutical goods in specialised stores. The profit for the financial year ending 31/12/2024 of LLC "Orchid-Pharm" was £4,090 and the aggregate amount of capital and reserves at the end of the year was £49,386.
5. Receivables
2024 2023
£ £
Due within one year
Other receivables 1,539 -
Called up share capital not paid - 100
1,539 100
6. Payables: Amounts Falling Due Within One Year
2024 2023
£ £
Other payables 253,428 222,817
Accruals and deferred income 4,320 4,470
Director's loan account 4,470 -
262,218 227,287
Page 4
Page 5
7. Share Capital
2024 2023
Allotted, called up and fully paid £ £
100 Ordinary Shares of £ 1.00 each 100 100
The company has one class of share capital which carries no right to fixed income.
Reserves
The retained earnings reserve represents cumulative profit or losses net of dividends paid and other adjustments.
8. Other Commitments
The total of future minimum lease payments under non-cancellable operating leases are as following:
2024 2023
£ £
Not later than one year 234 263
Later than one year and not later than five years 98 373
332 636
9. Post Balance Sheet Events
There have been no significant events between the year end and the date of approval of these accounts which would require a change to, or disclosure in, the financial statements.
10. Related Party Transactions
At the balance sheet date a balance of £4,470 (2023: £nil) was due to a shareholder of the company under non interest bearing loan repayable on demand.
11. Ultimate Controlling Party
The company's ultimate controlling party is A. Akhtyrskyi by virtue of his ownership of 100% of the issued share capital in the company.
Page 5